Teksöz S.Içhedef Ç.A.Özyüncü S.Müftüler F.Z.B.Ünak P.Medine I.E.Ertay T.Eren M.Ş.2019-10-272019-10-2720111084-9785https://doi.org/10.1089/cbr.2010.0854https://hdl.handle.net/11454/26805The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium ( 99mTc) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of 99mTc-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. 99mTc-D-PA-Glu exhibited more accumulation on PC-3 cells versus 99mTc-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of 99mTc-D-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. 99mTc-D-PA-Glu and 99mTc-D-PA have exhibited different biodistribution results. © 2011, Mary Ann Liebert, Inc.en10.1089/cbr.2010.0854info:eu-repo/semantics/closedAccess99mTcglucuronidationPC-3 cell linepenicillamineradiolabelingscintigraphyArticle26562363021950558Q2